Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Maase Inc. raises $50M via PIPE to fund AI computing and LLM work
• Velo3D names two executives to lead technology and operations